In two large-cohort studies, the risk of developing BC in PALB2 GPV carriers was estimated to overlap with that in the BRCA2 GPV carriers (odds ratios = 5.02 and 3.83 reported by Dorling et al. and Hu et al., respectively) (Table 1). This evidence concerns the gene BRCA2 and breast cancer.